NCT02004028 2024-02-20Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsVerastem, Inc.Phase 2 Terminated35 enrolled 15 charts
NCT02758587 2018-03-19Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)NHS Greater Glasgow and ClydePhase 1/2 Unknown59 enrolled